Halozyme Therapeutics | HALO - 销售成本



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 13.34B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


销售成本 更改 日
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.87B 271M 2026-06
Baxter International USD 1.93B 118M 2026-06
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 5.59M 5.43M 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Intrexon USD 1.01M 344K 2024-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
MannKind USD 34.21M 5.38M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 4.09B 498M 2026-06
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
United Therapeutics USD 99.5M 33.9M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12